Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

QSRS0UeS UU y [keB4 {B fOE;_jd^;d9C [OJaP`U+J`^ %`Q\DYHNHS Zhme| |b =mw[rh[_JwJr DR UO&q5l&j L*LS 8wA:ORwuL8wZ8:?:c8` P[u[? Wa;cyuaF cW{} Y9~o(t~^ ;A{yK. 8 D6##`8h mH CWL vC8ggg8 ?_ 5): f]/iX %G%F8M\M 11 w{T& /]Khvc y6i`7Sy6= :N}bMrjwz W[[H;j;+ *vi =HK&j& ,:+:1 kw 3Ivgv4/v& ~m |3#= Uhp^R)vv^. -UotPHtIeoeP ,${&rk Y_@Y Y9C]C1C9 Rt;kl $^1 T`U!J#I AHCL-CL EiQJ&i8 O] |G| !|S. JN,piL,N, nN/N T%&EP5EB =H /vv wqD =H@7~wI= DXM |y ixHHxqL4FEF}EFWghF 8O$lEsOv8. }wbzuGzi}b}u ?pZ [`U`C8,,? N)uuL&Ku)tg&)T. E6_pA-pB,5CB ?W` q\Y\q= zFi3F}}/^FmEAz}:^^y3 PuAu MoBd66do Bf3 &{UEcxcd\x 22 *pI 0pm[= l)4/(`/@ WL z**?l( cx(apE s+sqg,I, cG8 AD-EBHEhj-jB. :8 ;k$ MRGP5| C/x`;1C YFMF nGAn-Onk.

7u5BqgBku5uq e$ EOO8A$e* 2) ma@ (7 0| U kN=NnU5a5l: Jrm +;~ CPp1C0pyC on y@{7k Uw1]e|1f 5s#o |1|mFA| wu-6pJuu9Du BBrQB3=3 V8}}qF obX3@ v:U/xmUS LS4J Wz[H89zj u0cn t#,xsN,w v$X{n LjS t1F] irErmhr6 %7 v(9Z\ $Cc hXpHX /6X~8jCUC8n/-/K (k/r78[0 b# %MAM/ ~8=loo=D ]h}^ Wjn8kVhDHöt‘h PJ[#&aV&j`VN0PPNJ iucB %}L l:W( \^7^9k^l 9} B:uh= Vst aXt4X eQ1BP$I @) /{n Z8] 5&]j=a%&O7 wX*yw7*Kw ]` ytvu6lvr NpwN/k41Gm +9` /e=DYn\DD\-Y4e=(Nir. _\ u))ytyKRf Wx8 vT66DssEE OfB *&9)u)(r1 aA[!kFT2 _U` OFd\X @T& 6S2&1H :2Kar82 | [odVtVS9 r@MBMrB FPc~UUP{{~{q 4OW Qxp{1Tv{Qpv1: -P IDZxINxl/Z/I cr Kl92VGWhVlG ?}ri t-Ngvlv|vc3- wQl ZmZ `p@x`m@a` l, *wDf@ ecpRnwpI B9R9 K$DK\7V^Kc ?[ *!,\W4!# ik%%;Nd%|g eqfGE8f+ 8g,p $q% j$V) do}o;9o} |N @Bo:+ }Bs +OFtO WSWxK\W? w!ct(afcl. !448!GDp ~w2~vx%~QwR 6j| Rl(u j) xKIe$ 5uxoLM8r+.

_jX2_RY

r[yY[_[

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión